T Deplete

T Deplete is a fully human, afucosylated IgG1 monoclonal antibody that targets and eliminates CD161+ inflammatory/pathogenic T cells. This technology mediates durable immune effector-driven depletion of CD161⁺ cells through multiple mechanisms including potent NK cell-mediated ADCC, macrophage-mediated ADCP, neutrophil-mediated cytotoxicity, and complement-dependent cytotoxicity (CDC).

By selectively clearing pathogenic “bad actor” T-cell subsets, T Deplete spares healthy T cells that do not drive autoimmunity. The platform has demonstrated potent efficacy in non-human primate models, with IND-enabling safety studies currently underway to support advancement into first-in-human clinical trials for autoimmune disease.

References:
1.Fergusson JR et al. CD161 Defines a Transcriptional and Functional Phenotype across Distinct Human T Cell Lineages. Cell Reports. 2014;9:1075-1088.
2.Konduri V et al. CD8⁺CD161⁺ T Cells: Cytotoxic Memory Cells With High Therapeutic Potential. Frontiers in Immunology. 2021.
3.Tong B et al. Immunobiology Roles of the Human CD161 Receptor in T Cells. Frontiers in Immunology. 2025.
4.Billerbeck E et al. Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. Proceedings of the National Academy of Sciences (PNAS). 2010;107(7):3006-3011.
5.Cosmi et al. Human interleukin 17–producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med. 2008 Aug 4;205(8):1903–1916.
6.Maggi et al. CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. Eur J Immunol. 2010 Aug;40(8):2174-81.
7.Basdeo SA et al. Polyfunctional, Pathogenic CD161+ Th17 Lineage Cells Are Resistant to Regulatory T Cell-Mediated Suppression in the Context of Autoimmunity. Journal of Immunology. 2015;195(2):528-540. DOI: